Abstracts tagged "biomarkers and prevention"

Abstract Number: 37 • 2019 ACR/ARP Annual Meeting
Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis
Yanli Tong¹, Yunqiang Bai ², Yi Zhao ², Yi Liu ² and Yubin Luo ², ¹Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China (People's Republic), ²Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China (People's Republic)
Background/Purpose: Intestinal microbial dysbiosis in patients with rheumatoid arthritis (RA) has raised the interest in studying the role of intestinal microbes in the pathogenesis of…
Abstract Number: 2121 • 2017 ACR/ARHP Annual Meeting
Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies
Danielle Baldo¹, Alessandra Dellavance¹, Maria Lucia Ferraz² and Luis Eduardo C. Andrade^3,4, ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Gastroenterology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: Circulating autoantibodies precede clinical onset of several autoimmune diseases. The characteristics of the so-called pre-clinical stage of autoimmune diseases are poorly understood. Anti-mitochondria autoantibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].